PODN

Summary

PODN (podocan, HGNC:23174) is a protein-coding gene on chromosome 1p32.3, encoding Podocan (Q7Z5L7). Negatively regulates cell proliferation and cell migration.

The protein encoded by this gene is a member of the small leucine-rich repeat protein family and contains an amino terminal CX3CXCX7C cysteine-rich cluster followed by a leucine-rich repeat domain. Studies suggest that this protein could function to inhibit smooth muscle cell proliferation and migration following arterial injury.

Source: NCBI Gene 127435 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 137 total
• MANE Select transcript: NM_153703

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23174
Approved symbol	PODN
Name	podocan
Location	1p32.3
Locus type	gene with protein product
Status	Approved
Aliases	PCAN, PODOCAN, MGC24995, SLRR5A
Ensembl gene	ENSG00000174348
Ensembl biotype	protein_coding
OMIM	608661
Entrez	127435

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 26 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000312553, ENST00000371500, ENST00000395871, ENST00000471210, ENST00000471285, ENST00000490650, ENST00000618387, ENST00000673702, ENST00000673956, ENST00000895710, ENST00000895711, ENST00000895712, ENST00000895713, ENST00000895714, ENST00000895715, ENST00000895716, ENST00000895717, ENST00000895718, ENST00000895719, ENST00000895720, ENST00000895721, ENST00000961066, ENST00000961067, ENST00000961068, ENST00000961069, ENST00000961070, ENST00000961071, ENST00000961072, ENST00000961073

RefSeq mRNA: 3 — MANE Select: NM_153703 NM_001199080, NM_001199081, NM_153703

CCDS: CCDS573

Canonical transcript exons

ENST00000312553 — 11 exons

Exon	Start	End
ENSE00001190346	53078365	53079022
ENSE00001190355	53077685	53077800
ENSE00001226253	53080728	53080876
ENSE00001414470	53075862	53075971
ENSE00001415504	53074606	53074670
ENSE00001421216	53071535	53071628
ENSE00001425865	53077190	53077346
ENSE00001888902	53084513	53085494
ENSE00003619122	53081981	53082188
ENSE00003897816	53062213	53062308
ENSE00003897936	53069801	53070167

Expression profiles

Bgee: expression breadth ubiquitous, 202 present calls, max score 98.92.

FANTOM5 (CAGE): breadth broad, TPM avg 11.0739 / max 343.0754, expressed in 707 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
2906	10.1931	690
2910	0.4796	162
2909	0.3244	115
2905	0.0767	41

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right ovary	UBERON:0002118	98.92	gold quality
mucosa of stomach	UBERON:0001199	98.62	gold quality
left ovary	UBERON:0002119	98.50	gold quality
nerve	UBERON:0001021	98.30	gold quality
tibial nerve	UBERON:0001323	98.30	gold quality
right coronary artery	UBERON:0001625	98.14	gold quality
left uterine tube	UBERON:0001303	98.10	gold quality
gall bladder	UBERON:0002110	98.04	gold quality
omental fat pad	UBERON:0010414	97.93	gold quality
peritoneum	UBERON:0002358	97.89	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.35	gold quality
endocervix	UBERON:0000458	97.29	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.01	gold quality
left coronary artery	UBERON:0001626	96.78	gold quality
body of uterus	UBERON:0009853	96.67	gold quality
coronary artery	UBERON:0001621	96.64	gold quality
right atrium auricular region	UBERON:0006631	95.85	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.66	gold quality
lower esophagus	UBERON:0013473	95.61	gold quality
cardiac atrium	UBERON:0002081	95.48	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.44	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.39	gold quality
popliteal artery	UBERON:0002250	95.35	gold quality
tibial artery	UBERON:0007610	95.34	gold quality
apex of heart	UBERON:0002098	95.17	gold quality
right lobe of thyroid gland	UBERON:0001119	95.13	gold quality
ectocervix	UBERON:0012249	94.76	gold quality
aorta	UBERON:0000947	94.54	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.23	silver quality
sural nerve	UBERON:0015488	94.16	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	16.32
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

50 targeting PODN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-609	99.82	64.26	505
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-2392	99.43	67.50	708
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-6811-3P	98.62	66.54	944

Literature-anchored findings (GeneRIF, showing 3)

• PODN was characterized in cultured cells. (PMID:15063725)
• Podocan appears to be a potent negative regulator of the migration and proliferation of vascular smooth muscle cells. (PMID:24043300)
• It was apparent that HP upregulates miR-3180-5p, which inhibits the expression of PODN and promotes HBSMC proliferation via the cdk2 signaling pathway. (PMID:27608612)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	podn	ENSDARG00000019025
mus_musculus	Podn	ENSMUSG00000028600
rattus_norvegicus	Scp2	ENSRNOG00000011413

Paralogs (22): DCN (ENSG00000011465), RTN4R (ENSG00000040608), ASPN (ENSG00000106819), FLRT3 (ENSG00000125848), FLRT1 (ENSG00000126500), LRRC4 (ENSG00000128594), LRRC4B (ENSG00000131409), PODNL1 (ENSG00000132000), LRTM1 (ENSG00000144771), LRRC4C (ENSG00000148948), LRRTM1 (ENSG00000162951), LRRC15 (ENSG00000172061), LRRTM4 (ENSG00000176204), BGN (ENSG00000182492), LRRC19 (ENSG00000184434), FLRT2 (ENSG00000185070), GP1BA (ENSG00000185245), RTN4RL1 (ENSG00000185924), RTN4RL2 (ENSG00000186907), NYX (ENSG00000188937), LRRC66 (ENSG00000188993), LRRTM3 (ENSG00000198739)

Protein

Protein identifiers

Podocan — Q7Z5L7 (reviewed: Q7Z5L7)

All UniProt accessions (3): Q7Z5L7, A0A669KB13, A0A669KBI2

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates cell proliferation and cell migration.

Subunit / interactions. Binds to type I collagen.

Subcellular location. Secreted. Extracellular space. Extracellular matrix Cytoplasm Cytoplasm Cytoplasm.

Tissue specificity. Kidney, heart, liver, pancreas and vascular smooth muscle cells. Also detected in aortic intima (at protein level).

Post-translational modifications. N-glycosylated.

Miscellaneous. No signal peptide. No signal peptide. No signal peptide.

Similarity. Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class V subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
Q7Z5L7-1	1	yes
Q7Z5L7-2	2
Q7Z5L7-3	3
Q7Z5L7-4	4

RefSeq proteins (3): NP_001186009, NP_001186010, NP_714914* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR026906	LRR_5	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050333	SLRP	Family

Pfam: PF13306, PF13855

UniProt features (36 total): repeat 20, glycosylation site 4, splice variant 3, compositionally biased region 2, sequence variant 2, signal peptide 1, chain 1, domain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z5L7-F1	87.04	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (4): 214, 281, 299, 410

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): E2F_Q4, E2F_Q4_01, BENPORATH_ES_WITH_H3K27ME3, MYOGENIN_Q6, E2F4DP1_01, SP3_Q3, GGGTGGRR_PAX4_03, CHANDRAN_METASTASIS_DN, CAGCTG_AP4_Q5, SRF_Q5_01, E2F1DP1_01, E2F_Q3, E2F1DP2_01, GATA3_01, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT

GO Biological Process (2): negative regulation of cell population proliferation (GO:0008285), negative regulation of cell migration (GO:0030336)

GO Molecular Function (3): collagen binding (GO:0005518), protein binding (GO:0005515), extracellular matrix structural constituent conferring compression resistance (GO:0030021)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), cytoplasm (GO:0005737), extracellular matrix (GO:0031012), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
protein-containing complex binding	1
binding	1
extracellular matrix structural constituent	1
intracellular anatomical structure	1
external encapsulating structure	1

Protein interactions and networks

STRING

960 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PODN	ITGA11	Q9UKX5	474
PODN	COL1A2	P02464	451
PODN	POSTN	Q15063	438
PODN	COL3A1	P02461	433
PODN	BCAN	Q96GW7	366
PODN	HSPG2	P98160	365
PODN	EPYC	Q99645	361
PODN	CSGALNACT1	Q8TDX6	359
PODN	COL6A3	P12111	356
PODN	NYX	Q9GZU5	355
PODN	ISLR	O14498	354
PODN	LRR1	Q96L50	353
PODN	RAE1	P78406	353
PODN	CHST11	Q9NPF2	342
PODN	XYLT1	Q86Y38	326

IntAct

5 interactions, top by confidence:

A	B	Type	Score
	PODN	psi-mi:“MI:0915”(physical association)	0.400
PODN	HSPA5	psi-mi:“MI:0914”(association)	0.350
PODN	LRP5	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): CNPY4 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), LRP5 (Affinity Capture-MS), TUBB8 (Affinity Capture-MS), OS9 (Affinity Capture-MS), PODN (Two-hybrid), HSPA5 (Affinity Capture-MS), RCN1 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), FRAS1 (Affinity Capture-MS), IDS (Affinity Capture-MS), CBWD1 (Affinity Capture-MS), GALNS (Affinity Capture-MS), LRP6 (Affinity Capture-MS)

ESM2 similar proteins: A2VDH3, A6H793, B0BNK7, D2HFT7, D4ABX8, E9Q7T7, O75325, P22792, P40197, Q13641, Q149C3, Q1RMS4, Q2EEY0, Q2I0M4, Q3UVD5, Q3UY51, Q4KLL3, Q4R8Y9, Q50LG9, Q5I2M7, Q5I2M8, Q5PQV5, Q5VT99, Q6NUI6, Q6P3Y9, Q6PEZ8, Q6PJG9, Q6UY18, Q6ZSA7, Q7M6Z0, Q7TQ62, Q7Z5L7, Q80WD0, Q80WD1, Q80XU8, Q86UN2, Q86UN3, Q8BHA1, Q8BLY3, Q8K0S5

Diamond homologs: A3KNN3, A6H789, A6H793, A6NJW4, A8WHP9, E7FE13, F1MLX5, G5EFX6, O02678, O02833, O35367, O46378, O46379, O46542, O60938, O62702, O75093, O75094, O88279, O88280, O94813, P07359, P07585, P21793, P24014, P28654, P28675, P35858, P35859, P51884, P51885, P51886, P51888, P51890, P58874, P59034, P59035, P70186, P70389, P83286

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

137 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	113
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2954 predictions. Top by Δscore:

Variant	Effect	Δscore
1:53071525:A:AG	acceptor_gain	1.0000
1:53071526:C:G	acceptor_gain	1.0000
1:53071530:CCTA:C	acceptor_loss	1.0000
1:53071531:CTA:C	acceptor_loss	1.0000
1:53071532:TA:T	acceptor_loss	1.0000
1:53071533:A:AG	acceptor_gain	1.0000
1:53071534:G:GG	acceptor_gain	1.0000
1:53071534:GA:G	acceptor_gain	1.0000
1:53071534:GAAC:G	acceptor_gain	1.0000
1:53071628:GGTGA:G	donor_loss	1.0000
1:53071629:G:T	donor_loss	1.0000
1:53071630:T:G	donor_loss	1.0000
1:53075968:TGAG:T	donor_loss	1.0000
1:53075970:AG:A	donor_loss	1.0000
1:53075971:GGTC:G	donor_loss	1.0000
1:53077186:CCAG:C	acceptor_loss	1.0000
1:53077187:CA:C	acceptor_loss	1.0000
1:53077189:GGTCT:G	acceptor_gain	1.0000
1:53077344:AAG:A	donor_loss	1.0000
1:53077346:GG:G	donor_loss	1.0000
1:53077676:A:AG	acceptor_gain	1.0000
1:53077677:T:G	acceptor_gain	1.0000
1:53077681:CCAG:C	acceptor_loss	1.0000
1:53077681:CCAGA:C	acceptor_gain	1.0000
1:53077682:CAG:C	acceptor_loss	1.0000
1:53077682:CAGAA:C	acceptor_gain	1.0000
1:53077683:A:AG	acceptor_gain	1.0000
1:53077683:A:T	acceptor_loss	1.0000
1:53077683:AGAA:A	acceptor_gain	1.0000
1:53077684:G:GA	acceptor_gain	1.0000

AlphaMissense

4250 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000007938 (1:53062635 CG>C), RS1000042608 (1:53071459 C>A,T), RS1000240381 (1:53067954 G>T), RS1000319162 (1:53082559 G>C), RS1000655283 (1:53083775 G>A), RS1000667242 (1:53071604 C>T), RS1000708935 (1:53084052 G>C), RS1000795642 (1:53060945 C>T), RS1000831488 (1:53081405 G>A,C), RS1000863650 (1:53078154 A>T), RS1000966815 (1:53072607 C>A,G), RS1001017773 (1:53072819 G>A), RS1001128114 (1:53067650 C>T), RS1001322481 (1:53081043 G>A), RS1001392983 (1:53081199 A>G)

Disease associations

OMIM: gene MIM:608661 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST008839_90	Height	9.000000e-09

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	3
bisphenol A	affects cotreatment, increases expression, decreases methylation	2
Nickel	decreases expression	2
Aflatoxin B1	decreases methylation	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
ethyl-p-hydroxybenzoate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
incobotulinumtoxinA	increases expression	1
Dasatinib	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	increases methylation	1
Amiodarone	increases expression	1
Arsenic	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Calcitriol	decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Formaldehyde	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Oxygen	increases expression	1
Valproic Acid	decreases methylation	1
Vanadates	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Palmitic Acid	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer